

INFR5-14562: California Cell and Gene Therapy Manufacturing Network

Applicant: PD Dan Kaufman, UC San Diego

Updated Letters of Support

1. John M. Carethers, MD, MACP. UCSD Vice Chancellor for Health Sciences.

Dr. Carethers started his position at UCSD in January 2023, so was unable to provide a letter of support with the original proposal and wanted to do so now.

2. Catriona Jamieson, MD, PhD. UCSD Professor of Medicine and Director of Sanford Stem Cell Institute.

Dr. Jamieson wanted to provide an updated letter of support that specifically outlines the additional space now available to ACTL as part of the Sanford Stem Cell Institute.

UC San Diego

HEALTH SCIENCES

Dan S. Kaufman, MD, PhD
Professor
9500 Gilman Drive, MC 0695
La Jolla, CA. 92093-0694

May 23, 2023

Re: INFR5-14562, "UCSD Advanced Cell Therapy Laboratory" Support

Dear Dr. Kaufman,

I am very pleased to enthusiastically provide this letter of support for the UC San Diego Advanced Cell Therapy Laboratory (ACTL) as part of your CIRM INFR5 proposal to be part of the California Cell and Gene Therapy Manufacturing Network. As you know, I only recently joined UC San Diego as Vice Chancellor for Health Sciences in January of this year; therefore, I was not able to provide this letter of support at the time your proposal was submitted. However, in the interim I have been very pleased to meet with you and learn more about the vital role the ACTL plays for patient care at UC San Diego Health. I am very impressed that you have been able to provide clinical cell production for patients treated in multiple clinical trials. Your facility and team also play a key role in support of preclinical, pre-IND stage programs of both internal and external research groups. I am sure that the UC San Diego ACTL's inclusion in CIRM's California Cell and Gene Therapy Manufacturing Network will further bolster the impact of ACTL. I am also sure that you and your team will be valuable contributors and collaborators to other network members.

ACTL also plays a key role as part of the new Sanford Stem Cell Institute (SSCI). This Institute will now support a broad range of research and clinical services, as well as further improve clinical translation of novel cell and gene therapies. I understand that the SSCI has formally secured additional space for the process development work plans of ACTL, as outlined in your proposal. This will no doubt be helpful to better serve more ACTL clients, as the needs for your services are certainly growing. I also look forward to working with you and your team, as well as the SSCI, as we plan for additional GMP manufacturing space that will allow us to better meet the needs of internal UC San Diego projects, as well as clients and collaborators within the local biotech community. Additionally, your interactions with local CDMOs provides potential additional support for manufacturing needs. Again, these local manufacturing connections will certainly help bring important cell and gene therapies to UC San Diego Health patients.

I know we will be following up again soon about the ACTL plans moving forward. I look forward to hearing more about your interactions with CIRM's California Cell and Gene Therapy Manufacturing Network. If there is any other support I can provide in the interim, please let me know.



John M. Carethers, MD, MACP
Vice Chancellor for Health Sciences

UC San Diego
Sanford Stem Cell Institute

9500 Gilman Drive # 0695
La Jolla, CA 92093-0695
858-246-1453
cjamieson@ucsd.edu
stemcells.ucsd.edu

Catriona Jamieson, MD, PhD

Director
Sanford Stem Cell Institute
UC San Diego

May 25, 2023

Dan Kaufman, M.D., Ph.D.
Professor, Medicine
9500 Gilman Dr., Mail Code 0695
La Jolla, CA 92093-0695


Dear Professor Kaufman,

Re: INFR5-14562 “UCSD Advanced Cell Therapy Laboratory” Support


I wanted to provide this update to our strong support for your innovative CIRM INFR5-14562 grant application. Of particular relevance for this CIRM grant, the launching of the \$150 million Sanford Stem Cell Institute (SSCI) in September 2022 has provided a vital opportunity for expanding the ACTL to form a Sanford Stem Cell Institute Advanced Therapy Center as one of the six key centers within the Institute.

In addition to providing a \$500,000 per annum match as well as contingency funds for this grant application, the Sanford Stem Cell Institute has now procured space for the expansion of the Advanced Therapy Center. The Sanford Stem Cell Institute has secured space at the Center for Novel Therapeutics (CNT) located at 9310 Athena Circle, La Jolla, CA, 92037. The CNT is close to the current ACTL facility, and this space is ideally suited to facilitate academic collaboration and foster participation in the region’s largest community of researchers as it provides technology commercialization resources to entrepreneurs, including many local biotech companies in need of support for GMP cell and gene therapy manufacturing. The Sanford Stem Cell Institute will now be located on two floors in Suites 130 and 200, totaling 19,783 square feet, comprised of both wet and dry laboratory space. The Sanford Advanced Therapy Center will be housed within the first floor alongside the Sanford Stem Cell Innovation Center (See the following page for the space layout). This space corresponds with your estimate up to 5000 sq ft outlined in your CIRM proposal. We believe that the expansion of the current laboratory will support your goals for additional PD studies, training space, storage, and engagement of more local (and national) biotechnology companies that aim to provide novel clinical cell and gene therapies.

CNT/SSCI – Suite 130



CNT/SSCI – Suite 200



In summary, the SSCI enthusiastically supports your team's enhancements of internal processes that will result in robust cell and gene therapy GMP manufacturing capabilities with alacrity for our hopeful patients.

We are excited to see the developments of cellular therapies as well as the enhancements of internal processes that will result in better GMP manufacturing capabilities to our clients and patients.

Yours sincerely,

A handwritten signature in black ink, appearing to be 'C. Jamieson', written over a horizontal line.

Catriona Jamieson, MD, PhD
Director, Sanford Stem Cell Institute